US 12,226,639 B2
Klotho modulation
Howard J. Leonhardt, Mission Viejo, CA (US)
Assigned to LEONHARDT VENTURES LLC, Corona Del Mar, CA (US)
Filed by LEONHARDT VENTURES LLC, Corona Del Mar, CA (US)
Filed on Sep. 13, 2021, as Appl. No. 17/473,809.
Application 17/473,809 is a continuation in part of application No. PCT/US2020/021556, filed on Mar. 6, 2020.
Prior Publication US 2021/0402184 A1, Dec. 30, 2021
Int. Cl. A61N 1/36 (2006.01); A61N 1/04 (2006.01); A61N 1/32 (2006.01); A61N 1/08 (2006.01)
CPC A61N 1/36153 (2013.01) [A61N 1/044 (2013.01); A61N 1/0464 (2013.01); A61N 1/0468 (2013.01); A61N 1/326 (2013.01); A61N 1/36002 (2017.08); A61N 1/36003 (2013.01); A61N 1/36007 (2013.01); A61N 1/3601 (2013.01); A61N 1/36021 (2013.01); A61N 1/36025 (2013.01); A61N 1/36034 (2017.08); A61N 1/36157 (2013.01); A61N 1/3616 (2013.01); A61N 1/36167 (2013.01); A61N 1/36171 (2013.01); A61N 1/36175 (2013.01); A61N 1/36178 (2013.01); A61N 2001/083 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method of treating a cell, the method comprising:
stimulating the cell to express and/or release Klotho polypeptide by applying a bioelectric signal to the cell,
wherein the bioelectric signal has a square, biphasic waveform at 50% duty and a frequency selected from the group consisting of 5 Hz, 10 Hz, 20 Hz, 25 Hz, 50 Hz, 75 Hz, 100 Hz, 250 Hz, 500 Hz, 750 Hz, 2,500 Hz, 100,000 Hz, 500,000 Hz, and 1 MHz.